Terms: = Leukemia AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Treatment
151 results:
1. Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with atr Inhibitors.
Liu TT; Wang Q; Zhou Y; Ye B; Liu T; Yan L; Fan J; Xu J; Zhou Y; Xia Z; Deng X
J Med Chem; 2024 May; 67(9):7620-7634. PubMed ID: 38634707
[TBL] [Abstract] [Full Text] [Related]
2. Indigofera suffruticosa aerial parts extract induce G2/M arrest and atr/CHK1 pathway in Jurkat cells.
Tran HL; Lai KH; Chang HS; Chen YS; Wang HC; Yang SS; Chang HW; Hsu CM; Yen CH; Hsiao HH
BMC Complement Med Ther; 2024 Jan; 24(1):28. PubMed ID: 38195460
[TBL] [Abstract] [Full Text] [Related]
3. Suppression of DNMT1 combined with ATM or atr inhibitor as a therapeutic combination of acute myeloid leukemia.
Liu L; Hu X; Feng J; Lei A; Huang S; Liu X; Liu H; Luo L; Yao W
Anticancer Drugs; 2024 Mar; 35(3):251-262. PubMed ID: 38164802
[TBL] [Abstract] [Full Text] [Related]
4. Risk Factors for treatment-Related Amenorrhea in Female Survivors of Childhood and Adolescent Cancer: 10-Year Experiences at Oncofertility Clinic in Korean Tertiary Center.
Park SJ; Choi JY; Kang HJ; Lee YJ; Lee YA; Han JY; Kim SW; Kim H; Ku SY
J Adolesc Young Adult Oncol; 2024 Feb; 13(1):162-169. PubMed ID: 38064519
[No Abstract] [Full Text] [Related]
5. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
Molica S; Tam C; Allsup D; Polliack A
Hematol Oncol; 2024 Jan; 42(1):e3238. PubMed ID: 37937506
[TBL] [Abstract] [Full Text] [Related]
6. CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, atr or WEE1.
Pfeiffer C; Grandits AM; Asnagli H; Schneller A; Huber J; Zojer N; Schreder M; Parker AE; Bolomsky A; Beer PA; Ludwig H
Leukemia; 2024 Jan; 38(1):181-192. PubMed ID: 37898670
[TBL] [Abstract] [Full Text] [Related]
7. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast Cancer.
Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
[TBL] [Abstract] [Full Text] [Related]
9. Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
Thompson PA; Keating MJ; Ferrajoli A; Jain N; Peterson CB; Garg N; Wang SA; Jorgensen JL; Kadia TM; Bose P; Pemmaraju N; Short NJ; Wierda WG
Leukemia; 2023 Jul; 37(7):1444-1453. PubMed ID: 37138019
[TBL] [Abstract] [Full Text] [Related]
10. Glyoxalase 1 inhibitor BBGC suppresses the progression of chronic lymphocytic leukemia and promotes the efficacy of Palbociclib.
Tang J; Zhong J; Yang Z; Su Q; Mo W
Biochem Biophys Res Commun; 2023 Apr; 650():96-102. PubMed ID: 36774689
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia.
Xu Z; Pan B; Miao Y; Li Y; Qin S; Liang J; Kong Y; Zhang X; Tang J; Xia Y; Zhu H; Wang L; Li J; Wu J; Xu W
Clin Exp Med; 2023 Oct; 23(6):2651-2662. PubMed ID: 36738306
[TBL] [Abstract] [Full Text] [Related]
12. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.
Barszczewska-Pietraszek G; Drzewiecka M; Czarny P; Skorski T; Śliwiński T
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613762
[TBL] [Abstract] [Full Text] [Related]
13. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
Cyr MG; Mhibik M; Qi J; Peng H; Chang J; Gaglione EM; Eik D; Herrick J; Venables T; Novick SJ; Courouble VV; Griffin PR; Wiestner A; Rader C
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36442911
[TBL] [Abstract] [Full Text] [Related]
14. p53 as a unique target of action of cisplatin in acute leukaemia cells.
Kumar S; Tchounwou PB
J Cell Mol Med; 2022 Sep; 26(17):4727-4739. PubMed ID: 35946055
[TBL] [Abstract] [Full Text] [Related]
15. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Strati P; Coleman M; Champion R; Ma S; Patti C; Levy MY; Lossos IS; Geethakumari PR; Lam S; Calvo R; Higgins K; Budde LE
Br J Haematol; 2022 Oct; 199(1):76-85. PubMed ID: 35861370
[TBL] [Abstract] [Full Text] [Related]
16. Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis.
Tomic B; Smoljo T; Lalic H; Dembitz V; Batinic J; Batinic D; Bedalov A; Visnjic D
Sci Rep; 2022 Jul; 12(1):11344. PubMed ID: 35790845
[TBL] [Abstract] [Full Text] [Related]
17.
Kayabasi C; Yilmaz Susluer S; Balci Okcanoglu T; Ozmen Yelken B; Mutlu Z; Goker Bagca B; Caliskan Kurt C; Saydam G; Durmuskahya C; Kayalar H; Ozbilgin A; Biray Avci C; Gunduz C
Nutr Cancer; 2022; 74(10):3679-3691. PubMed ID: 35608652
[No Abstract] [Full Text] [Related]
18. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
Aslan B; Kismali G; Iles LR; Manyam GC; Ayres ML; Chen LS; Gagea M; Bertilaccio MTS; Wierda WG; Gandhi V
Blood Cancer J; 2022 May; 12(5):80. PubMed ID: 35595730
[TBL] [Abstract] [Full Text] [Related]
19. Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells.
Mamidi MK; Mahmud H; Maiti GP; Mendez MT; Fernandes SM; Vesely SK; Holter-Chakrabarty J; Brown JR; Ghosh AK
Leukemia; 2022 Jul; 36(7):1806-1817. PubMed ID: 35568768
[TBL] [Abstract] [Full Text] [Related]
20. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
Ghia EM; Rassenti LZ; Choi MY; Quijada-Álamo M; Chu E; Widhopf GF; Kipps TJ
Leukemia; 2022 Jun; 36(6):1609-1618. PubMed ID: 35418613
[TBL] [Abstract] [Full Text] [Related]
[Next]
